[1]
Martinez-Naharro A,Hawkins PN,Fontana M, Cardiac amyloidosis. Clinical medicine (London, England). 2018 Apr 1;
[PubMed PMID: 29700090]
[2]
Dubrey SW,Hawkins PN,Falk RH, Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart (British Cardiac Society). 2011 Jan;
[PubMed PMID: 21148582]
[3]
Ruberg FL,Grogan M,Hanna M,Kelly JW,Maurer MS, Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2019 Jun 11;
[PubMed PMID: 31171094]
[4]
AbouEzzeddine OF,Davies DR,Scott CG,Fayyaz AU,Askew JW,McKie PM,Noseworthy PA,Johnson GB,Dunlay SM,Borlaug BA,Chareonthaitawee P,Roger VL,Dispenzieri A,Grogan M,Redfield MM, Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA cardiology. 2021 Aug 25;
[PubMed PMID: 34431962]
[5]
Kelly JW,Colon W,Lai Z,Lashuel HA,McCulloch J,McCutchen SL,Miroy GJ,Peterson SA, Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Advances in protein chemistry. 1997;
[PubMed PMID: 9338081]
Level 3 (low-level) evidence
[6]
Liz MA,Mar FM,Franquinho F,Sousa MM, Aboard transthyretin: From transport to cleavage. IUBMB life. 2010 Jun;
[PubMed PMID: 20503435]
[7]
Cornwell GG 3rd,Sletten K,Johansson B,Westermark P, Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin. Biochemical and biophysical research communications. 1988 Jul 29;
[PubMed PMID: 3135807]
[8]
Westermark P,Sletten K,Johansson B,Cornwell GG 3rd, Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proceedings of the National Academy of Sciences of the United States of America. 1990 Apr;
[PubMed PMID: 2320592]
[9]
Coelho T,Maurer MS,Suhr OB, THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Current medical research and opinion. 2013 Jan;
[PubMed PMID: 23193944]
Level 3 (low-level) evidence
[11]
Pinney JH,Whelan CJ,Petrie A,Dungu J,Banypersad SM,Sattianayagam P,Wechalekar A,Gibbs SD,Venner CP,Wassef N,McCarthy CA,Gilbertson JA,Rowczenio D,Hawkins PN,Gillmore JD,Lachmann HJ, Senile systemic amyloidosis: clinical features at presentation and outcome. Journal of the American Heart Association. 2013 Apr 22;
[PubMed PMID: 23608605]
[12]
Rozenbaum MH,Large S,Bhambri R,Stewart M,Whelan J,van Doornewaard A,Dasgupta N,Masri A,Nativi-Nicolau J, Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review. Cardiology and therapy. 2021 Jun;
[PubMed PMID: 33877591]
[13]
Gillmore JD,Maurer MS,Falk RH,Merlini G,Damy T,Dispenzieri A,Wechalekar AD,Berk JL,Quarta CC,Grogan M,Lachmann HJ,Bokhari S,Castano A,Dorbala S,Johnson GB,Glaudemans AW,Rezk T,Fontana M,Palladini G,Milani P,Guidalotti PL,Flatman K,Lane T,Vonberg FW,Whelan CJ,Moon JC,Ruberg FL,Miller EJ,Hutt DF,Hazenberg BP,Rapezzi C,Hawkins PN, Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016 Jun 14;
[PubMed PMID: 27143678]
[14]
Lindmark K,Pilebro B,Sundström T,Lindqvist P, Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC heart failure. 2021 Feb;
[PubMed PMID: 33205581]
[15]
González-López E,Gallego-Delgado M,Guzzo-Merello G,de Haro-Del Moral FJ,Cobo-Marcos M,Robles C,Bornstein B,Salas C,Lara-Pezzi E,Alonso-Pulpon L,Garcia-Pavia P, Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. European heart journal. 2015 Oct 7;
[PubMed PMID: 26224076]
[16]
Cornwell GG 3rd,Murdoch WL,Kyle RA,Westermark P,Pitkänen P, Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. The American journal of medicine. 1983 Oct;
[PubMed PMID: 6624768]
[17]
Mohammed SF,Mirzoyev SA,Edwards WD,Dogan A,Grogan DR,Dunlay SM,Roger VL,Gertz MA,Dispenzieri A,Zeldenrust SR,Redfield MM, Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC. Heart failure. 2014 Apr;
[PubMed PMID: 24720917]
[18]
Castaño A,Narotsky DL,Hamid N,Khalique OK,Morgenstern R,DeLuca A,Rubin J,Chiuzan C,Nazif T,Vahl T,George I,Kodali S,Leon MB,Hahn R,Bokhari S,Maurer MS, Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. European heart journal. 2017 Oct 7;
[PubMed PMID: 29019612]
[19]
Witteles RM,Bokhari S,Damy T,Elliott PM,Falk RH,Fine NM,Gospodinova M,Obici L,Rapezzi C,Garcia-Pavia P, Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC. Heart failure. 2019 Aug;
[PubMed PMID: 31302046]
[20]
Lane T,Fontana M,Martinez-Naharro A,Quarta CC,Whelan CJ,Petrie A,Rowczenio DM,Gilbertson JA,Hutt DF,Rezk T,Strehina SG,Caringal-Galima J,Manwani R,Sharpley FA,Wechalekar AD,Lachmann HJ,Mahmood S,Sachchithanantham S,Drage EPS,Jenner HD,McDonald R,Bertolli O,Calleja A,Hawkins PN,Gillmore JD, Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019 Jul 2;
[PubMed PMID: 31109193]
Level 2 (mid-level) evidence
[21]
Bruno M,Castaño A,Burton A,Grodin JL, Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. Heart failure reviews. 2021 Jan;
[PubMed PMID: 32794090]
[22]
Buxbaum JN,Ruberg FL, Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genetics in medicine : official journal of the American College of Medical Genetics. 2017 Jul;
[PubMed PMID: 28102864]
[23]
Connors LH,Sam F,Skinner M,Salinaro F,Sun F,Ruberg FL,Berk JL,Seldin DC, Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study. Circulation. 2016 Jan 19;
[PubMed PMID: 26660282]
[24]
Donnellan E,Wazni OM,Hanna M,Elshazly MB,Puri R,Saliba W,Kanj M,Vakamudi S,Patel DR,Baranowski B,Cantillon D,Dresing T,Jaber WA, Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies. JACC. Clinical electrophysiology. 2020 Sep;
[PubMed PMID: 32972546]
[25]
Khanna S,Lo P,Cho K,Subbiah R, Ventricular Arrhythmias in Cardiac Amyloidosis: A Review of Current Literature. Clinical Medicine Insights. Cardiology. 2020;
[PubMed PMID: 33088185]
[26]
Falk RH,Alexander KM,Liao R,Dorbala S, AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. Journal of the American College of Cardiology. 2016 Sep 20;
[PubMed PMID: 27634125]
[27]
Pellikka PA,Holmes DR Jr,Edwards WD,Nishimura RA,Tajik AJ,Kyle RA, Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Archives of internal medicine. 1988 Mar;
[PubMed PMID: 3341867]
[28]
Quarta CC,Gonzalez-Lopez E,Gilbertson JA,Botcher N,Rowczenio D,Petrie A,Rezk T,Youngstein T,Mahmood S,Sachchithanantham S,Lachmann HJ,Fontana M,Whelan CJ,Wechalekar AD,Hawkins PN,Gillmore JD, Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. European heart journal. 2017 Jun 21;
[PubMed PMID: 28605421]
[29]
Vrana JA,Gamez JD,Madden BJ,Theis JD,Bergen HR 3rd,Dogan A, Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009 Dec 3;
[PubMed PMID: 19797517]
[30]
Rapezzi C,Merlini G,Quarta CC,Riva L,Longhi S,Leone O,Salvi F,Ciliberti P,Pastorelli F,Biagini E,Coccolo F,Cooke RM,Bacchi-Reggiani L,Sangiorgi D,Ferlini A,Cavo M,Zamagni E,Fonte ML,Palladini G,Salinaro F,Musca F,Obici L,Branzi A,Perlini S, Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009 Sep 29;
[PubMed PMID: 19752327]
[32]
Pilebro B,Suhr OB,Näslund U,Westermark P,Lindqvist P,Sundström T, (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Upsala journal of medical sciences. 2016;
[PubMed PMID: 26849806]
[33]
Grogan M,Scott CG,Kyle RA,Zeldenrust SR,Gertz MA,Lin G,Klarich KW,Miller WL,Maleszewski JJ,Dispenzieri A, Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. Journal of the American College of Cardiology. 2016 Sep 6;
[PubMed PMID: 27585505]
[34]
Rosenbaum AN,AbouEzzeddine OF,Grogan M,Dispenzieri A,Kushwaha S,Clavell A,Daly RC,Edwards BS, Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis. Transplantation. 2018 Nov;
[PubMed PMID: 29677073]
[35]
Maurer MS,Bokhari S,Damy T,Dorbala S,Drachman BM,Fontana M,Grogan M,Kristen AV,Lousada I,Nativi-Nicolau J,Cristina Quarta C,Rapezzi C,Ruberg FL,Witteles R,Merlini G, Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation. Heart failure. 2019 Sep;
[PubMed PMID: 31480867]
Level 3 (low-level) evidence
[36]
Mints YY,Doros G,Berk JL,Connors LH,Ruberg FL, Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC heart failure. 2018 Oct;
[PubMed PMID: 29916559]
Level 1 (high-level) evidence
[37]
John RM, Arrhythmias in Cardiac Amyloidosis. The Journal of innovations in cardiac rhythm management. 2018 Mar;
[PubMed PMID: 32477799]
[38]
Feng D,Syed IS,Martinez M,Oh JK,Jaffe AS,Grogan M,Edwards WD,Gertz MA,Klarich KW, Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 2009 May 12;
[PubMed PMID: 19414641]
[39]
Nakagawa M,Sekijima Y,Yazaki M,Tojo K,Yoshinaga T,Doden T,Koyama J,Yanagisawa S,Ikeda S, Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2016;
[PubMed PMID: 26852880]
[40]
Westermark P,Westermark GT,Suhr OB,Berg S, Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. Upsala journal of medical sciences. 2014 Aug;
[PubMed PMID: 24620715]
[41]
Geller HI,Singh A,Alexander KM,Mirto TM,Falk RH, Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis. JAMA. 2017 Sep 12;
[PubMed PMID: 28898370]
[42]
Hassan W,Al-Sergani H,Mourad W,Tabbaa R, Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Texas Heart Institute journal. 2005;
[PubMed PMID: 16107109]
[43]
Gertz M,Adams D,Ando Y,Beirão JM,Bokhari S,Coelho T,Comenzo RL,Damy T,Dorbala S,Drachman BM,Fontana M,Gillmore JD,Grogan M,Hawkins PN,Lousada I,Kristen AV,Ruberg FL,Suhr OB,Maurer MS,Nativi-Nicolau J,Quarta CC,Rapezzi C,Witteles R,Merlini G, Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC family practice. 2020 Sep 23;
[PubMed PMID: 32967612]
Level 3 (low-level) evidence
[44]
Mussinelli R,Salinaro F,Alogna A,Boldrini M,Raimondi A,Musca F,Palladini G,Merlini G,Perlini S, Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc. 2013 May;
[PubMed PMID: 23714086]
[45]
Dungu J,Sattianayagam PT,Whelan CJ,Gibbs SD,Pinney JH,Banypersad SM,Rowczenio D,Gilbertson JA,Lachmann HJ,Wechalekar A,Gillmore JD,Hawkins PN,Anderson LJ, The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. American heart journal. 2012 Jul;
[PubMed PMID: 22795285]
[46]
Syed IS,Glockner JF,Feng D,Araoz PA,Martinez MW,Edwards WD,Gertz MA,Dispenzieri A,Oh JK,Bellavia D,Tajik AJ,Grogan M, Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC. Cardiovascular imaging. 2010 Feb;
[PubMed PMID: 20159642]
[47]
Pagourelias ED,Mirea O,Duchenne J,Van Cleemput J,Delforge M,Bogaert J,Kuznetsova T,Voigt JU, Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis: A Head-to-Head Comparison of Deformation and Nondeformation Parameters. Circulation. Cardiovascular imaging. 2017 Mar;
[PubMed PMID: 28298286]
[48]
Quarta CC,Solomon SD,Uraizee I,Kruger J,Longhi S,Ferlito M,Gagliardi C,Milandri A,Rapezzi C,Falk RH, Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014 May 6;
[PubMed PMID: 24563469]
[49]
Zhao L,Tian Z,Fang Q, Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC cardiovascular disorders. 2016 Jun 7;
[PubMed PMID: 27267362]
Level 1 (high-level) evidence
[50]
Martinez-Naharro A,Treibel TA,Abdel-Gadir A,Bulluck H,Zumbo G,Knight DS,Kotecha T,Francis R,Hutt DF,Rezk T,Rosmini S,Quarta CC,Whelan CJ,Kellman P,Gillmore JD,Moon JC,Hawkins PN,Fontana M, Magnetic Resonance in Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology. 2017 Jul 25;
[PubMed PMID: 28728692]
[51]
Carvalho FP,Erthal F,Azevedo CF, The Role of Cardiac MR Imaging in the Assessment of Patients with Cardiac Amyloidosis. Magnetic resonance imaging clinics of North America. 2019 Aug;
[PubMed PMID: 31279449]
[52]
Dungu JN,Valencia O,Pinney JH,Gibbs SD,Rowczenio D,Gilbertson JA,Lachmann HJ,Wechalekar A,Gillmore JD,Whelan CJ,Hawkins PN,Anderson LJ, CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC. Cardiovascular imaging. 2014 Feb;
[PubMed PMID: 24412186]
[53]
Stats MA,Stone JR, Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology. 2016 Sep-Oct;
[PubMed PMID: 27469499]
[54]
Castano A,Haq M,Narotsky DL,Goldsmith J,Weinberg RL,Morgenstern R,Pozniakoff T,Ruberg FL,Miller EJ,Berk JL,Dispenzieri A,Grogan M,Johnson G,Bokhari S,Maurer MS, Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA cardiology. 2016 Nov 1;
[PubMed PMID: 27557400]
Level 2 (mid-level) evidence
[55]
Bokhari S,Castaño A,Pozniakoff T,Deslisle S,Latif F,Maurer MS, (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circulation. Cardiovascular imaging. 2013 Mar 1;
[PubMed PMID: 23400849]
[56]
Phull P,Sanchorawala V,Connors LH,Doros G,Ruberg FL,Berk JL,Sarosiek S, Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2018 Mar;
[PubMed PMID: 29424556]
[57]
Ash S,Shorer E,Ramgobin D,Vo M,Gibbons J,Golamari R,Jain R,Jain R, Cardiac amyloidosis-A review of current literature for the practicing physician. Clinical cardiology. 2021 Mar;
[PubMed PMID: 33595871]
[58]
Bhuiyan T,Helmke S,Patel AR,Ruberg FL,Packman J,Cheung K,Grogan D,Maurer MS, Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS). Circulation. Heart failure. 2011 Mar;
[PubMed PMID: 21191093]
[59]
Pollak A,Falk RH, Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest. 1993 Aug;
[PubMed PMID: 8339658]
[60]
El-Am EA,Dispenzieri A,Melduni RM,Ammash NM,White RD,Hodge DO,Noseworthy PA,Lin G,Pislaru SV,Egbe AC,Grogan M,Nkomo VT, Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis. Journal of the American College of Cardiology. 2019 Feb 12;
[PubMed PMID: 30732713]
[61]
Epstein AE,DiMarco JP,Ellenbogen KA,Estes NA 3rd,Freedman RA,Gettes LS,Gillinov AM,Gregoratos G,Hammill SC,Hayes DL,Hlatky MA,Newby LK,Page RL,Schoenfeld MH,Silka MJ,Stevenson LW,Sweeney MO,Smith SC Jr,Jacobs AK,Adams CD,Anderson JL,Buller CE,Creager MA,Ettinger SM,Faxon DP,Halperin JL,Hiratzka LF,Hunt SA,Krumholz HM,Kushner FG,Lytle BW,Nishimura RA,Ornato JP,Page RL,Riegel B,Tarkington LG,Yancy CW,American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices).,American Association for Thoracic Surgery.,Society of Thoracic Surgeons., ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Journal of the American College of Cardiology. 2008 May 27;
[PubMed PMID: 18498951]
Level 1 (high-level) evidence
[62]
Kristen AV,Dengler TJ,Hegenbart U,Schonland SO,Goldschmidt H,Sack FU,Voss F,Becker R,Katus HA,Bauer A, Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart rhythm. 2008 Feb;
[PubMed PMID: 18242546]
[63]
Varr BC,Zarafshar S,Coakley T,Liedtke M,Lafayette RA,Arai S,Schrier SL,Witteles RM, Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart rhythm. 2014 Jan;
[PubMed PMID: 24121001]
[64]
Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, Schmidt H, Waddington-Cruz M, Campistol JM, Bettencourt BR, Vaishnaw A, Gollob J, Adams D. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet journal of rare diseases. 2015 Sep 4:10():109. doi: 10.1186/s13023-015-0326-6. Epub 2015 Sep 4
[PubMed PMID: 26338094]
[65]
Yarlas A,Lovley A,McCausland K,Brown D,Vera-Llonch M,Conceição I,Karam C,Khella S,Obici L,Waddington-Cruz M, Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR. Neurology and therapy. 2021 Aug 5;
[PubMed PMID: 34355354]
Level 2 (mid-level) evidence
[66]
Maurer MS,Elliott P,Merlini G,Shah SJ,Cruz MW,Flynn A,Gundapaneni B,Hahn C,Riley S,Schwartz J,Sultan MB,Rapezzi C,ATTR-ACT Study Investigators., Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Circulation. Heart failure. 2017 Jun;
[PubMed PMID: 28611125]
Level 1 (high-level) evidence
[67]
Berk JL,Suhr OB,Obici L,Sekijima Y,Zeldenrust SR,Yamashita T,Heneghan MA,Gorevic PD,Litchy WJ,Wiesman JF,Nordh E,Corato M,Lozza A,Cortese A,Robinson-Papp J,Colton T,Rybin DV,Bisbee AB,Ando Y,Ikeda S,Seldin DC,Merlini G,Skinner M,Kelly JW,Dyck PJ,Diflunisal Trial Consortium., Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013 Dec 25;
[PubMed PMID: 24368466]
Level 1 (high-level) evidence
[68]
Cristóbal Gutiérrez H,Pelayo-Negro AL,Gómez Gómez D,Martín Vega MÁ,Valero Domínguez M, Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review. European journal of hospital pharmacy : science and practice. 2020 Jul;
[PubMed PMID: 32587078]
Level 3 (low-level) evidence
[69]
Maurer MS,Schwartz JH,Gundapaneni B,Elliott PM,Merlini G,Waddington-Cruz M,Kristen AV,Grogan M,Witteles R,Damy T,Drachman BM,Shah SJ,Hanna M,Judge DP,Barsdorf AI,Huber P,Patterson TA,Riley S,Schumacher J,Stewart M,Sultan MB,Rapezzi C,ATTR-ACT Study Investigators., Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. The New England journal of medicine. 2018 Sep 13;
[PubMed PMID: 30145929]
[70]
Damy T,Garcia-Pavia P,Hanna M,Judge DP,Merlini G,Gundapaneni B,Patterson TA,Riley S,Schwartz JH,Sultan MB,Witteles R, Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. European journal of heart failure. 2021 Feb;
[PubMed PMID: 33070419]
[71]
McDonagh TA,Metra M,Adamo M,Gardner RS,Baumbach A,Böhm M,Burri H,Butler J,Čelutkienė J,Chioncel O,Cleland JGF,Coats AJS,Crespo-Leiro MG,Farmakis D,Gilard M,Heymans S,Hoes AW,Jaarsma T,Jankowska EA,Lainscak M,Lam CSP,Lyon AR,McMurray JJV,Mebazaa A,Mindham R,Muneretto C,Francesco Piepoli M,Price S,Rosano GMC,Ruschitzka F,Kathrine Skibelund A,ESC Scientific Document Group., 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal. 2021 Sep 21
[PubMed PMID: 34447992]
[72]
Rozenbaum MH,Garcia A,Grima D,Tran D,Bhambri R,Stewart M,Li B,Heeg B,Postma M,Masri A, Health Impact of Tafamidis in Transthyretin Amyloid Cardiomyopathy patients: An Analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the Open-Label Long-term Extension Studies. European heart journal. Quality of care
[PubMed PMID: 33895806]
Level 2 (mid-level) evidence
[73]
Vollmar J,Schmid JC,Hoppe-Lotichius M,Barreiros AP,Azizi M,Emrich T,Geber C,Schad A,Weyer V,Otto G,Heise M,Mittler J,Birklein F,Lang H,Galle PR,Zimmermann T, Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study. Transplant international : official journal of the European Society for Organ Transplantation. 2018 Nov;
[PubMed PMID: 30091268]
[74]
Sousa M,Monohan G,Rajagopalan N,Grigorian A,Guglin M, Heart transplantation in cardiac amyloidosis. Heart failure reviews. 2017 May;
[PubMed PMID: 28281017]
[75]
Gillmore JD,Damy T,Fontana M,Hutchinson M,Lachmann HJ,Martinez-Naharro A,Quarta CC,Rezk T,Whelan CJ,Gonzalez-Lopez E,Lane T,Gilbertson JA,Rowczenio D,Petrie A,Hawkins PN, A new staging system for cardiac transthyretin amyloidosis. European heart journal. 2018 Aug 7;
[PubMed PMID: 29048471]